CN113795274A - 一种治疗肌萎缩侧索硬化的方法和药物 - Google Patents

一种治疗肌萎缩侧索硬化的方法和药物 Download PDF

Info

Publication number
CN113795274A
CN113795274A CN202080034475.6A CN202080034475A CN113795274A CN 113795274 A CN113795274 A CN 113795274A CN 202080034475 A CN202080034475 A CN 202080034475A CN 113795274 A CN113795274 A CN 113795274A
Authority
CN
China
Prior art keywords
plasminogen
mice
activity
group
pathway activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080034475.6A
Other languages
English (en)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tailunji International Co ltd
Original Assignee
Tailunji International Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tailunji International Co ltd filed Critical Tailunji International Co ltd
Publication of CN113795274A publication Critical patent/CN113795274A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

本发明公开了一种治疗肌萎缩侧索硬化(ALS)的方法，包括给药受试者治疗有效量的纤溶酶原途径激活剂。本发明还公开了用于治疗肌萎缩侧索硬化的包含纤溶酶原途径激活剂的药物组合物、制品、试剂盒。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202080034475.6A 2019-05-10 2020-05-11 一种治疗肌萎缩侧索硬化的方法和药物 Pending CN113795274A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019086431 2019-05-10
CNPCT/CN2019/086431 2019-05-10
PCT/CN2020/089632 WO2020228681A1 (zh) 2019-05-10 2020-05-11 一种治疗肌萎缩侧索硬化的方法和药物

Publications (1)

Publication Number Publication Date
CN113795274A true CN113795274A (zh) 2021-12-14

Family

ID=73289345

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080034475.6A Pending CN113795274A (zh) 2019-05-10 2020-05-11 一种治疗肌萎缩侧索硬化的方法和药物

Country Status (7)

Country Link
US (1) US20220218799A1 (zh)
EP (1) EP3967322A4 (zh)
JP (1) JP7455457B2 (zh)
KR (1) KR20220007122A (zh)
CN (1) CN113795274A (zh)
CA (1) CA3139850A1 (zh)
WO (1) WO2020228681A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024784A2 (en) * 1999-10-04 2001-04-12 Fujisawa Pharmaceutical Co., Ltd. New use
WO2010124185A1 (en) * 2009-04-23 2010-10-28 University Of Cincinnati Allantoin administration for the treatment of neurodegenerative disease and neurotrauma
WO2011062762A2 (en) * 2009-11-19 2011-05-26 President And Fellows Of Harvard College Angiogenin and variants thereof for treatment of neurodegenerative diseases
WO2012145428A2 (en) * 2011-04-21 2012-10-26 Washington University Altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US7235529B2 (en) * 1996-10-11 2007-06-26 Human Genome Sciences, Inc. Brain-associated inhibitor of tissue-type plasminogen activator
WO2006023530A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
WO2006136419A2 (en) * 2005-06-24 2006-12-28 Wilex Ag Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases
US20090104639A1 (en) * 2007-09-12 2009-04-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomarkers for motor neuron disease
WO2009146178A1 (en) * 2008-04-15 2009-12-03 President And Fellows Of Harvard College Angiogenin and amyotrophic lateral sclerosis
KR20120050442A (ko) * 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
US8465727B2 (en) * 2009-10-06 2013-06-18 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers for the diagnosis of ALS
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024784A2 (en) * 1999-10-04 2001-04-12 Fujisawa Pharmaceutical Co., Ltd. New use
WO2010124185A1 (en) * 2009-04-23 2010-10-28 University Of Cincinnati Allantoin administration for the treatment of neurodegenerative disease and neurotrauma
WO2011062762A2 (en) * 2009-11-19 2011-05-26 President And Fellows Of Harvard College Angiogenin and variants thereof for treatment of neurodegenerative diseases
WO2012145428A2 (en) * 2011-04-21 2012-10-26 Washington University Altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid

Also Published As

Publication number Publication date
CA3139850A1 (en) 2020-11-19
KR20220007122A (ko) 2022-01-18
WO2020228681A1 (zh) 2020-11-19
US20220218799A1 (en) 2022-07-14
JP2022531937A (ja) 2022-07-12
JP7455457B2 (ja) 2024-03-26
EP3967322A1 (en) 2022-03-16
EP3967322A4 (en) 2022-06-08

Similar Documents

Publication Publication Date Title
WO2017101870A1 (zh) 一种预防或治疗糖尿病性视网膜病变的方法
WO2022105788A1 (zh) 一种提高bdnf水平的方法和药物
CN116490200A (zh) 一种提高ngf水平的方法和药物
CN111905103A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
TWI787767B (zh) 一種治療亨廷頓病的方法和藥物
TWI787732B (zh) 一種預防和治療多發性硬化症的方法和藥物
WO2021143906A1 (zh) 一种治疗神经损伤及其相关病症的方法
KR20220158036A (ko) 파킨슨병의 치료 방법 및 약물
CN113795274A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
WO2021170099A1 (zh) 一种预防和治疗血压异常病症的方法和药物
US20230181699A1 (en) Method and drug for treating spinal muscular atrophy
TW202228766A (zh) 一種治療神經損傷及其相關病症的方法
TW202408566A (zh) 一種治療神經損傷及其相關病症的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination